April 14, 2021
Business News

BeiGene Announces Closing of Collaboration with Novartis to Develop and Commercialize Anti-PD-1 Antibody Tislelizumab in North America, Europe and Japan


CAMBRIDGE, Mass. & BEIJING–()–BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced the closing of the collaboration and license agreement with Novartis Pharma AG, previously announced on January 11, 2021, to develop, manufacture, and commercialize BeiGene’s anti-PD-1 antibody tislelizumab in the United States, Canada, Mexico, member countries of the European Union, United Kingdom, Norway, Switzerland, Iceland, Liechtenstein, Russia, and Japan. The companies have agreed to jointly develop tislelizumab in these licensed countries, with Novartis responsible for regulatory submissions after a…



Click here to view the original article.

Related Posts

You might also like ...

AON Splash Image
OSI Systems Receives $16 Million Contract for Security Inspection Systems
AON Splash Image
Resumen: Smiths Detection confirma que BioFlash es capaz de detectar la COVID-19 en el aire
Africa’s Best Corporate-Startup Collaboration Accelerator, Startupbootcamp AfriTech, Now Open for Applications from the Most Disruptive Startups